Within the FGF19 transgenic HCC model, 1A6 treatment significantly reduced HCC incidence, with treated mice exhibiting minimal liver tumor formation, a substantial decrease in liver weight, and a reduction in tumor volume. This evidence concerns the gene FGF19 and neoplasm.